Abdominal Incision Injection of Liposomal Bupivacaine and Opioid Use After Laparotomy for Gynecologic Malignancies.

@article{Kalogera2016AbdominalII,
  title={Abdominal Incision Injection of Liposomal Bupivacaine and Opioid Use After Laparotomy for Gynecologic Malignancies.},
  author={Eleftheria Kalogera and Jamie N. Bakkum-Gamez and Amy L. Weaver and James P. Moriarty and Bijan J Borah and Carrie L Langstraat and Christopher J. Jankowski and Jenna K. Lovely and William A. Cliby and Sean C. Dowdy},
  journal={Obstetrics and gynecology},
  year={2016},
  volume={128 5},
  pages={
          1009-1017
        }
}
OBJECTIVE To investigate opioid use and pain scores associated with incisional injection of liposomal bupivacaine compared with bupivacaine hydrochloride after laparotomy for gynecologic malignancies. METHODS A retrospective cohort study was conducted to compare abdominal incision infiltration with liposomal bupivacaine with bupivacaine hydrochloride after modification of a pre-existing enhanced recovery pathway. Patients undergoing staging laparotomy or complex cytoreductive surgery under… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 12 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

and Drug Administration

U. S. Foo
FDA label approved on 10/28/2011 (PDF) for EXPAREL. Silver Spring (MD): U.S. Food and Drug Administration. Available at: http://www. accessdata.fda.gov/drugsatfda_docs/label/2011/022496s000lbl.pdf. Retrieved September 18, • 2016